The TAME trial was supposed to answer whether metformin can delay aging in humans. As of 2026, it is still running with no efficacy results — but its regulatory legacy is already reshaping the field.
Idea only
the starting rung
Shown in animals
30 Jul 2013doi.orgTested in humans
31 Jan 2018doi.orgIn clinical use
not yet
In wide use
not yet
Stage refers to evidence for slowing aging, not other medical uses.
Short answer: No TAME efficacy results have been published. Its proposed protocol is a research plan, not evidence that metformin slows aging in people; check AFAR or ClinicalTrials.gov for current status.
The Targeting Aging with Metformin (TAME) project was designed to test whether metformin could delay several age-related diseases in older adults. No TAME efficacy results have been published. Funding and recruitment status can change, so check AFAR or ClinicalTrials.gov before describing the study as enrolling or running.
This page separates the trial’s proposed design from evidence already available about metformin. For the broader clinical evidence and safety discussion, see our metformin longevity review.
TAME stands for Targeting Aging with Metformin. The proposed project would test whether metformin can delay the development or progression of multiple age-related chronic diseases, rather than focusing on only one diagnosis. Public descriptions have presented it as a proposed multisite research project; verify funding and recruitment against a dated AFAR or registry update.
That distinction matters: a proposed design is not the same as a registered, recruiting trial, and a trial plan is not a result. The planned population, endpoints, number of sites, dose, duration, and enrollment details may change before a study starts. Check AFAR and the official clinical-trial registry for current status rather than repeating older plans as settled facts.
The research question is important because observational associations and diabetes treatment experience cannot determine whether metformin benefits otherwise healthy people as an aging intervention. A well-run randomized trial could help answer that question, but there are no TAME efficacy data to interpret today.
No supplement has been shown to reproduce a hypothetical TAME result. Berberine is sometimes compared with metformin because both have been studied for metabolic markers, but that does not make them interchangeable drugs or establish that either slows aging in healthy people. Study populations, doses, formulations, and safety monitoring differ.
If you are considering berberine for a specific metabolic goal, review the berberine evidence and product guide and discuss interactions with a clinician or pharmacist. Do not combine it with a prescription glucose-lowering drug without medical advice.
Until funding, registration, recruitment, and a final protocol are documented by reliable sources, details in older articles should be treated as plans rather than confirmed operational facts.
The absence of results is not evidence that metformin works or that it does not work for aging. It means the central question remains unanswered by this proposed trial. A reader should distinguish the drug’s established use for type 2 diabetes from off-label use in people without diabetes.
Look for an update from AFAR, a registered record in ClinicalTrials.gov, and ultimately a peer-reviewed protocol or results paper. Confirm the date and the exact study before relying on a news headline. A funding announcement alone would not establish that enrollment has begun, and enrollment would not establish efficacy.
If the trial launches and completes its planned follow-up, its results could inform whether metformin changes the risk or timing of the prespecified age-related outcomes in the enrolled population. It would not automatically show that every healthy adult should take metformin, nor would a result in one age or risk group establish the same balance of benefit and harm in another.
Interpretation would depend on the final protocol, recruitment, adherence, adverse events, outcome definitions, and how results are reported. Until those details and results exist, there is no basis for presenting a dose or start date as a longevity protocol.
TAME is a proposed research project, not a completed test of metformin for aging. No efficacy results have been published. The status can change, so verify it with AFAR or the trial registry before relying on an older update.
Metformin remains a prescription medicine with established clinical use for type 2 diabetes. Whether its benefits outweigh risks for people without diabetes as a longevity intervention is not established by TAME. Discuss off-label use, kidney function, vitamin B12 monitoring, side effects, and exercise goals with a prescriber. The metformin page reviews those considerations.
A protocol dose is not a recommendation for someone to start the drug. Trial eligibility criteria are also not a shortcut to personal prescribing. Metformin can cause gastrointestinal effects and may affect vitamin B12 status during longer use; kidney function and other medical factors matter. A clinician can decide whether a prescription has an indication and what monitoring is appropriate.
The “geroscience” rationale proposes that a medicine affecting several pathways might delay more than one age-related condition. That is a scientific hypothesis, not a demonstrated treatment effect. Even a positive result would need to be understood in the context of absolute benefit, adverse events, and which outcomes changed. It would not prove that metformin slows every biological aging process.
A status page should be read as dated administrative information. Funding, ethics review, site activation, participant recruitment, and published results are separate milestones. A notice about one does not establish the others. A registered protocol describes intended methods; it does not show whether the intervention changed outcomes. When reporting status, quote the source date and exact milestone, and avoid calling the study “underway” unless active status is documented by the registry or sponsor.
For people already prescribed metformin, do not stop or change it because of a longevity article. For people without diabetes, do not begin a prescription drug based on an anticipated trial. The absence of TAME results is exactly why careful, clinician-led decisions remain necessary.
People who take a medicine in ordinary care differ from people who do not. They may have different diagnoses, health-care access, habits, and reasons for receiving treatment. That makes observational comparisons useful for generating questions, but difficult to interpret as proof that a medicine caused a difference in aging outcomes. Random assignment and a comparison group are intended to reduce some of those biases.
A well-designed aging trial also needs outcomes that matter to participants. A shift in a laboratory marker may be interesting, but it is not automatically a meaningful delay in disease, disability, or death. A multi-outcome study must prespecify how events are defined and analyzed, and report adverse events alongside any benefit. These design choices are part of why a proposed trial cannot be treated as a result before it is conducted.
When you see a headline about TAME, check whether it refers to funding, registration, recruitment, a protocol, interim data, or final results. Those are different milestones. A press release about support or planning does not mean participants have been enrolled. A registered record does not mean the intervention has been proven. A preprint or conference abstract may not provide the same level of detail as a complete peer-reviewed report.
Look for the date of the source and whether it describes the current trial or an earlier proposal. Confirm the study name and sponsor, then compare the population and outcomes with the claim in the headline. If no dated primary update is linked, treat the operational status as uncertain.
The TAME project does not answer whether an individual should take metformin today. A prescriber weighs the person’s diagnosis, kidney function, other medicines, side effects, goals, and expected benefit. For diabetes, metformin may be prescribed for an established indication; that decision is separate from taking it off-label for longevity.
If your interest is prevention, ask what outcome you hope to change and whether an intervention has evidence in people like you. Exercise, sleep, vaccination, and cardiovascular risk management have their own evidence and should not be set aside while waiting for a trial that has not reported results. A clinician can also explain whether monitoring for vitamin B12 or other effects is appropriate for a person already using metformin.
Is the TAME trial recruiting in 2026?
No current recruitment status is established here. Check AFAR and the official registry for a dated update; do not rely on older claims that it is enrolling.
Have TAME results shown that metformin slows aging?
No. No TAME efficacy results have been published.
Does the proposed TAME dose tell me what to take?
No. A proposed protocol is not personal medical advice or a recommendation to start a prescription medicine.
Is metformin an anti-aging drug for healthy people?
That has not been established. Its approved clinical use and the unproven longevity question are different.
What should I discuss with a prescriber?
Discuss the reason for use, kidney function, vitamin B12, side effects, medication interactions, and how the decision fits your exercise and health goals.